Rochester, NY 6/24/2009 1:20:26 AM
Early Afternoon Report - ONTY - Oncothyreon Shares Rose Monday on Stimuvax Study, Stuggling Tuesday Afternoon - Sourced WhisperFromWallStreet.com
Oncothyreon Inc
Early Afternoon Report - ONTY - Oncothyreon Shares Rose Monday on Stimuvax Study, Stuggling Tuesday Afternoon - Sourced WhisperFromWallStreet.com
WhisperfromWallStreet.com is a FREE award winning newsletter that specializes in sending alerts to our subscribers on stocks we think are going to run, why we think so, as well as teaching you how to become a better trader. We scan hundreds of stocks a day to find those that meet our criteria and when we find one, we send you an alert. We have sent out 40 alerts so far in 2009 with an average price gain of over 80%. Please join risk free and see for yourself.
Sign up for our FREE alerts at WhisperfromWallStreet.com
---
Oncothyreon Inc,ONTY
2.87 Down 0.16 (5.28%) 2:08pm ET
Shares of Oncothyreon Inc. jumped Monday after the company said its partner started a late-stage study on the potential breast cancer treatment Stimuvax.
The stock gained 37 cents, or 16.2 percent, to reach $2.65 in afternoon trading. The shares have traded between 62 cents and $4.89 over the last 52 weeks.
Merck KGaA, based in Germany, expects to enroll more than 900 patients worldwide in the study. The key goal is progression-free survival, or how long a patient survives without the cancer progressing.
ABOUT
Oncothyreon Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing therapeutic products for the treatment of cancer. The company's lead product candidate includes Stimuvax, a cancer vaccine in Phase III development for non-small cell lung cancer. Its pipeline of clinical and pre-clinical stage proprietary small molecule product candidates comprise PX-478, a Phase I trial product, which is a small molecule inhibitor of hypoxia inducible factor-1a for advanced metastatic cancer; PX-866, an inhibitor of the phosphatidylinositol-3-kinase /PTEN/Akt pathway indicated for advanced solid tumors and glioma; PX-12, a Phase II trial product for pancreatic cancer; and PX-316, a chemical inhibitor that prevents translocation, the movement of the target protein in the cell to its site of activation.
Last Trade: 2.87
Day's Range: 2.81 - 3.36
52wk Range: 0.62 - 4.89
Volume: 1,363,282
---
Here are a few alerts our WhisperfromWallStreet.com subscribers enjoyed.
SPNG 1000%
AMNG 241%
RKBD 300%
UTRM 169%
TLLE 266%
Sign up to receive free stock alerts
---
Disclaimer: Full disclaimer at http://whisperfromwallstreet.com/disclaimer.php
WhisperfromWallStreet.com (WFWS) based upon information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by WFWS to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. WFWS is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.whisperfromwallstreet.com or mentioned herein. WFWS may have been compensated with shares or with cash from third party shareholders or the company on behalf of one or more of the companies mentioned in this opinion.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and WFWS undertakes no obligation to update such statements.
This is not a solicitation to buy or sell any securities. WhisperfromWallStreet.com, nor any of its affiliates are not registered investment advisors or a broker dealers. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
CONTACT: WhisperFromWallStreet.com
